• Direct preclinical research for novel engineered cytokines and synthetic antibody-based cytokine receptor agonists (SCAs) for autoimmunity and oncology. • Mentor 6 direct reports responsible for functional in vitro screening and mechanistic characterization of cytokine and SCA candidates using primary monocyte, T, NK, or B cell or cell line assays for IL-10, IL-12, IL-18, IL-22, and additional undisclosed collaborator programs. Assays used in my group include flow cytometry immunophenotyping, intracellular signaling and cytokine production, MSD chemiluminescence, bulk and single cell RNA-Seq, immunofluorescence, RT-PCR, and various functional cell assays. • Lead scientific efforts for IL-12 partial agonist (STK-026) which avoids NK-mediated toxicities but retains anti-tumor efficacy and activity on activated T cells. Analyze and interpret data, author pre-IND, study reports, conference posters, and scientific manuscript. • Support clinical biomarker flow cytometry design and data analysis for IL-2R alpha-biased IL-2 partial agonist STK-012 and STK-009/SYNCAR-1 Orthologous IL-2/CAR-T programs • Support (JRC member) Merck collaboration that successfully delivered lead and backup humanized Hu/Cyno XR Surrogate Cytokine (VHH) Agonists for autoimmunity which blunt inflammatory Th17 responses and inhibit colitis• Prepare and present pre-clinical data in BD discussions resulting in $40+M deal with Sanofi for engineered IL-10 agonists for autoimmunity designed to avoid T cell activation and resultant anemia but keep immunosuppressive functions. Co-author collaboration study and milestone plan • Support and co-manage autoimmune and metabolic IL-22 partial agonist program for retained epithelial repair and metabolic control but with reduced off-target (skin) toxicity• Co-manage discovery and characterization of IL-18 surrogate cytokine agonists for oncology. Design targeting strategies to direct activity towards activated T cells and away from NK cells

Group leader for ImmunoOncology programs using long-acting TransCon and TransCon Hydrogel technologies,

Lead Scientist / Project Manager for Nanobody (VHH) development against undisclosed ImmunoOncology (I/O) target X in collaboration with Ablynx (Ghent, Belgium).Design, create and validate Nanobody selection and screening workflow including immunogen design, recombinant protein and cell line transfectant specificity panel, and cell based functional assays for mouse, NHP and Human. Design in vivo experiments to test proof of biology with newly created surrogate anti-mouse target X reagents in relevant I/O combinations.

Developing cell based assays for identifying novel cancer immunotherapies.Performing detailed characterization of novel cancer immunotherapy leads using cell based functional assays and primary human cells.

Nodality Inc. is a privately held emerging biotechnology company focused on patient-specific classification of disease, licensed from Stanford University and the laboratory of Dr. Garry P. Nolan. Nodality’s technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The Company’s novel technology platform can address many aspects of drug development including biomarker identification and analysis, drug discovery research and development, patient stratification, and monitoring the pharmacodynamics of therapeutics. Nodality’s primary focus is hematological and autoimmune disorders.www.nodalityinc.com

Performed research at UCSF in the Lanier Lab studying human immunology and mechanisms of controlling immune activation by surface receptors.

Performed structure function analyses on human IFN alpha variants. Molecular Biology, Cloning, Protein Expression and Purification.